Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15611470 | 0.87 | ALDH1A1 (0.35) | — | |
| SCHEMBL15612758 | 0.87 | CA12 (0.36) | CA12CA1CA2CA9USP2 | |
| SCHEMBL6138643 | 0.83 | LMNA (0.33) | — | |
| SCHEMBL15612475 | 0.80 | CA12 (0.37) | CA12CA1CA2CA9USP2 | |
| SCHEMBL15612038 | 0.79 | — | — | |
| SCHEMBL29155521 | 0.79 | CA12 (0.35) | CA12CA1CA2CA9USP2 | |
| SCHEMBL15611857 | 0.78 | CA12 (0.36) | CA12CA1CA2CA9USP2 | |
| SCHEMBL15970143 | 0.78 | — | — | |
| SCHEMBL15611887 | 0.78 | ALDH1A1 (0.35) | — | |
| SCHEMBL15611769 | 0.78 | MEN1 (0.44) | CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249276-B2 | Conjugated diene polymer end-modified with alkoxysilane derivative | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2016-02-02 | — | — | US | claimed |
| US-20140243447-A1 | CONJUGATED DIENE POLYMER END-MODIFIED WITH ALKOXYSILANE DERIVATIVE | KOREAN KUMHO PETROCHEMICAL CO., LTD. (KR) | 2014-08-28 | — | — | US | claimed |
| US-20140088320-A1 | ALKYLALKOXYSILANE COMPOUNDS CONTAINING ETHER GROUP AND DIALKYLAMINO GROUP AND PROCESS FOR PREPARING THE COMPOUNDS | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2014-03-27 | — | — | US | claimed |
| US-9434751-B2 | Alkylalkoxysilane compounds containing ether group and dialkylamino group and process for preparing the compounds | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2016-09-06 | — | — | US | disclosed |
| US-9249276-B2 | Conjugated diene polymer end-modified with alkoxysilane derivative | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2016-02-02 | — | — | US | disclosed |
| US-20140243447-A1 | CONJUGATED DIENE POLYMER END-MODIFIED WITH ALKOXYSILANE DERIVATIVE | KOREAN KUMHO PETROCHEMICAL CO., LTD. (KR) | 2014-08-28 | — | — | US | disclosed |
| US-20140088320-A1 | ALKYLALKOXYSILANE COMPOUNDS CONTAINING ETHER GROUP AND DIALKYLAMINO GROUP AND PROCESS FOR PREPARING THE COMPOUNDS | KOREA KUMHO PETROCHEMICAL CO., LTD. (KR) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088320-A1 | ALKYLALKOXYSILANE COMPOUNDS CONTAINING ETHER GROUP AND DIALKYLAMINO GROUP AND PROCESS FOR PREPARING THE COMPOUNDS | ALKBH3, ALKBH2, AGPS | CA12 2602/4885CA1 3336/4885CA2 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.